share_log

Mizuho Reiterates Buy on Relmada Therapeutics, Maintains $26 Price Target

Benzinga ·  Jun 15, 2023 21:00

Mizuho analyst Vamil Divan reiterates Relmada Therapeutics (NASDAQ:RLMD) with a Buy and maintains $26 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment